Study

Permissions

Patient data

RELAY

Palliative radiation therapy was permitted for irradiating small areas of painful metastases that could not be managed adequately using systemic or local analgesics.

Such areas must not have constituted progressive disease (PD) or met Response Evaluation Criteria in Solid Tumors (RECIST) criteria for PD.1,2

No data on patients is available.1,2

RAINBOW

Palliative radiation to symptomatic sites of disease was allowed per the clinical study protocol.1,3

No information is available as no patients in the ramucirumab plus paclitaxel arm received concurrent palliative radiation.1,3

REACH-2

palliative radiation to symptomatic sites of disease was allowed per the clinical study protocol. 

7 patients (3.6%) in the ramucirumab arm and 2 patients (2.1%) in the placebo arm received palliative radiotherapy.1,4

Study

Permissions

RAINBOW

Patients could participate if they stopped radiation 28 days prior to randomization.3

REGARD

Patients could participate if they stopped radiation for gastric cancer 2 weeks prior to randomization.5

REVEL

Patients could participate if they stopped 

• chest radiotherapy 28 days prior to randomization
• local or palliative radiation treatment 7 days prior to randomization and provided that 25% or less of total bone marrow had been irradiated
• CNS radiation 14 days prior to randomization.6

RAISE

Patients could participate if they stopped

• any radiation 14 days prior to randomization, or
• wide-field (full-dose pelvic) 28 days prior to randomization.7

REACH-2

Patients could participate if they stopped any hepatic locoregional therapy, including radiation, 28 days prior to randomization.4

RELAY

Patients could participate if they stopped 

• local palliation or prevention of symptoms (such as pain, bleeding, or obstruction) 7 days prior to enrollment and provided that 25% or less of total bone marrow had been irradiated. 
• thoracic radiotherapy 28 days before enrollment.2